

ICOMET - Analysis of the genetic expression contribution towards the development of metastases in colon cancer patients with no lymph node involvement

Head :Olschwang Sylviane, CENTRE DE RECHERCHE EN CANCÉROLOGIE DE MARSEILLE UMR891 INSERM Saurin , CELLULES ENDOCRINES ET DIGESTIVES NORMALES ET NÉOPLASIQUES U865 INSERM

Last update : 07/24/2014 | Version : 1 | ID : 60160

General

Identification

Detailed name Analysis of the genetic expression contribution towards the development of metastases in colon cancer patients with no lymph node involvement

Sign or acronym ICOMET

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation no. iCOMET/IPC 2009-002. Avis CCTIRS et CPP

General Aspects

Medical area Cancer research

Health determinants Genetic

Others (details) Colon cancer with no lymph node involvement

Keywords Health episodes, onset, metastases

Scientific investigator(s) (Contact)

Name of the director Olschwang

Surname Sylviane

Address 13009 MARSEILLE

Phone + 33 (0)4 91 22 34 06

Email sylviane.olschwang@inserm.fr

Unit CENTRE DE RECHERCHE EN CANCÉROLOGIE DE MARSEILLE UMR891 INSERM

Organization INSERM

Name of the director	Saurin
Address	69003 LYON
Phone	+ 33 (0)4 78 86 16 89
Email	jean-christophe.saurin@chu-lyon.fr
Unit	CELLULES ENDOCRINES ET DIGESTIVES NORMALES ET NÉOPLASIQUES U865 INSERM
Organization	INSERM

Collaborations

Participation in projects, networks and consortia	Yes
---	-----

Funding

Funding status	Private
----------------	---------

Details	ASSOCIATION POUR LE RECHERCHE CONTRE LE CANCER (ARC) LABORATOIRE SERVIER INTERNATIONAL
---------	--

Governance of the database

Sponsor(s) or organisation(s) responsible	CLCC INSTITUT PAOLI-CALMETTES
Organisation status	Public

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Prospective Inclusion cut-off date: 01/08/2013 Patients with colon cancer, 1/3 having metastases

Clinical data (detail)	Direct physical measures Medical registration
Biological data (detail)	Type of samples taken: Blood and fixed tissue
Presence of a biobank	Yes
Contents of biobank	Tissues DNA
Details of biobank content	DNA bank, tumour bank
Health parameters studied	Health event/morbidity Health event/mortality
Procedures	
Data collection method	Clinical examinations: direct input Biological analysis: direct input
Participant monitoring	Yes
Details on monitoring of participants	Follow-up duration: 54 months
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Data may be used by academic teams Access subject to favourable opinion of the scientific committee Raw clinical and biological database available Biological specimen aliquots for target characterisation available - To be decided if data may be used by industrial teams
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only